Symbols / CODX $2.41 +4.33%
CODX Chart
About
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 5.05M |
| Enterprise Value | -5.28M | Income | -32.18M | Sales | 507.89K |
| Book/sh | 24.82 | Cash/sh | 5.64 | Dividend Yield | — |
| Payout | 0.00% | Employees | 132 | IPO | — |
| P/E | — | Forward P/E | -0.20 | PEG | — |
| P/S | 9.94 | P/B | 0.10 | P/C | — |
| EV/EBITDA | 0.15 | EV/Sales | -10.40 | Quick Ratio | 3.36 |
| Current Ratio | 3.81 | Debt/Eq | 3.70 | LT Debt/Eq | — |
| EPS (ttm) | -29.40 | EPS next Y | -12.15 | EPS Growth | — |
| Revenue Growth | -77.30% | Earnings | 2026-03-31 | ROA | -37.92% |
| ROE | -62.12% | ROIC | — | Gross Margin | 34.03% |
| Oper. Margin | -48.24% | Profit Margin | 0.00% | Shs Outstand | 2.10M |
| Shs Float | 1.94M | Short Float | 3.90% | Short Ratio | 1.19 |
| Short Interest | — | 52W High | 46.50 | 52W Low | 2.05 |
| Beta | 1.40 | Avg Volume | 144.97K | Volume | 48.01K |
| Target Price | — | Recom | None | Prev Close | $2.31 |
| Price | $2.41 | Change | 4.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.65
Latest analyst target
3. DCF / Fair value
$-176.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.65
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-26 | init | Maxim Group | — → Buy | $2 |
| 2025-11-24 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-10-28 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-10-16 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-09-19 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-09-17 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-15 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-28 | init | D. Boral Capital | — → Buy | $10 |
| 2025-03-28 | main | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2024-11-11 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-08-12 | main | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-06-17 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-05-13 | main | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-03-15 | main | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2023-12-29 | reit | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2023-11-13 | main | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2023-08-14 | main | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2023-05-15 | reit | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2023-03-20 | down | HC Wainwright & Co. | Buy → Neutral | $3 |
| 2023-02-23 | reit | HC Wainwright & Co. | — → Buy | $6 |
- Co-Diagnostics sets Mar. 31 webcast to review 2025 results - Stock Titan ue, 17 Mar 2026 13
- Co-Diagnostics Announces Reverse Stock Split - PR Newswire ue, 30 Dec 2025 08
- Utah's Co-Diagnostics joins Seoul global healthcare conference - Stock Titan Mon, 16 Mar 2026 13
- CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform - Yahoo Finance Wed, 31 Dec 2025 08
- Co-Diagnostics Regains Compliance with Nasdaq Listing Requirements - PR Newswire ue, 10 Mar 2026 13
- Co-Diagnostics announces 1-for-30 reverse stock split - Yahoo Finance Wed, 31 Dec 2025 08
- Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies - PR Newswire hu, 12 Mar 2026 13
- Nasdaq clears Co-Diagnostics: shares set to resume trading Mar. 11 - Stock Titan ue, 10 Mar 2026 07
- CoDiagnostics (CODX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance ue, 02 Dec 2025 08
- Japan patent backs Co-Diagnostics' compact PCR device for rapid infection tests - Stock Titan hu, 12 Mar 2026 13
- Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - PR Newswire ue, 28 Oct 2025 07
- Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai - PR Newswire Mon, 09 Feb 2026 08
- Biotech Co-Diagnostics shrinks share count 30-to-1 to stay on Nasdaq - Stock Titan ue, 30 Dec 2025 08
- Co-Diagnostics Reports Third Quarter 2025 Financial Results - PR Newswire hu, 13 Nov 2025 08
- Lab conferences boost CoSara's India network for future TB PCR tests - Stock Titan Mon, 12 Jan 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 57499 | — | — | MURPHY EDWARD L. | Director | — | 2025-11-21 00:00:00 | D | nan |
| 1 | 57499 | — | — | DURENARD EUGENE A | Director | — | 2025-11-21 00:00:00 | D | nan |
| 2 | 134167 | — | — | BROWN BRIAN LEE | Chief Financial Officer | — | 2025-11-21 00:00:00 | D | nan |
| 3 | 56667 | — | — | ABBOTT RICHARD DAVID | President | — | 2025-11-21 00:00:00 | D | nan |
| 4 | 57499 | — | — | SERBIN RICHARD S | Director | — | 2025-11-21 00:00:00 | D | nan |
| 5 | 163333 | — | — | EGAN DWIGHT H. | Chief Executive Officer | — | 2025-11-21 00:00:00 | D | nan |
| 6 | 57499 | — | — | NELSON JAMES B | Director | — | 2025-11-21 00:00:00 | D | nan |
| 7 | 228333 | — | — | SERBIN RICHARD S | Director | — | 2025-11-21 00:00:00 | D | nan |
| 8 | 575833 | — | — | EGAN DWIGHT H. | Chief Executive Officer | — | 2025-11-21 00:00:00 | D | nan |
| 9 | 228333 | — | — | NELSON JAMES B | Director | — | 2025-11-21 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 334.72K | 243.31K | -1.87M | -8.74K |
| TaxRateForCalcs | 0.21 | 0.07 | 0.24 | 0.20 |
| NormalizedEBITDA | -40.30M | -44.81M | -2.68M | 46.44M |
| TotalUnusualItems | 1.59M | 3.33M | -7.63M | -44.35K |
| TotalUnusualItemsExcludingGoodwill | 1.59M | 3.33M | -7.63M | -44.35K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -37.64M | -35.33M | -14.24M | 36.66M |
| ReconciledDepreciation | 1.38M | 1.23M | 1.28M | 335.36K |
| ReconciledCostOfRevenue | 999.12K | 4.18M | 5.48M | 11.57M |
| EBITDA | -38.70M | -41.48M | -10.31M | 46.40M |
| EBIT | -40.08M | -42.71M | -11.59M | 46.06M |
| NetInterestIncome | 1.09M | 1.16M | 704.04K | 45.63K |
| InterestIncome | 1.09M | 1.16M | 704.04K | 45.63K |
| NormalizedIncome | -38.90M | -38.42M | -8.48M | 36.69M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -37.64M | -35.33M | -14.24M | 36.66M |
| TotalExpenses | 44.00M | 49.52M | 45.81M | 51.82M |
| TotalOperatingIncomeAsReported | -40.08M | -42.71M | -26.98M | 46.06M |
| DilutedAverageShares | 1.01M | 978.22K | 1.05M | 996.79K |
| BasicAverageShares | 1.01M | 978.22K | 1.05M | 962.49K |
| DilutedEPS | -37.20 | -36.00 | -13.50 | 36.90 |
| BasicEPS | -37.20 | -36.00 | -13.50 | 38.10 |
| DilutedNIAvailtoComStockholders | -37.64M | -35.33M | -14.24M | 36.66M |
| NetIncomeCommonStockholders | -37.64M | -35.33M | -14.24M | 36.66M |
| NetIncome | -37.64M | -35.33M | -14.24M | 36.66M |
| NetIncomeIncludingNoncontrollingInterests | -37.64M | -35.33M | -14.24M | 36.66M |
| NetIncomeContinuousOperations | -37.64M | -35.33M | -14.24M | 36.66M |
| TaxProvision | 57.37K | -2.78M | -4.61M | 8.98M |
| PretaxIncome | -37.58M | -38.11M | -18.85M | 45.64M |
| OtherIncomeExpense | 1.41M | 3.43M | -7.96M | -474.79K |
| SpecialIncomeCharges | 723.17K | 1.09M | -7.63M | -44.35K |
| GainOnSaleOfPPE | 8.29K | -2.58K | -138.12K | -44.35K |
| ImpairmentOfCapitalAssets | 0.00 | 15.39M | 0.00 | |
| RestructuringAndMergernAcquisition | -714.88K | -1.09M | -7.90M | 0.00 |
| EarningsFromEquityInterest | -186.07K | 100.70K | -332.97K | -430.43K |
| GainOnSaleOfSecurity | 870.75K | 2.24M | ||
| NetNonOperatingInterestIncomeExpense | 1.09M | 1.16M | 704.04K | 45.63K |
| InterestIncomeNonOperating | 1.09M | 1.16M | 704.04K | 45.63K |
| OperatingIncome | -40.08M | -42.71M | -11.59M | 46.06M |
| OperatingExpense | 43.00M | 45.33M | 40.33M | 40.25M |
| DepreciationAmortizationDepletionIncomeStatement | 1.38M | 1.23M | 1.28M | 335.36K |
| DepreciationAndAmortizationInIncomeStatement | 1.38M | 1.23M | 1.28M | 335.36K |
| ResearchAndDevelopment | 20.98M | 22.96M | 17.44M | 14.96M |
| SellingGeneralAndAdministration | 20.64M | 21.14M | 21.61M | 24.95M |
| SellingAndMarketingExpense | 4.48M | 6.86M | 7.34M | 13.40M |
| GeneralAndAdministrativeExpense | 16.16M | 14.28M | 14.26M | 11.55M |
| OtherGandA | 16.16M | 14.28M | 14.26M | 11.55M |
| GrossProfit | 2.92M | 2.63M | 28.74M | 86.31M |
| CostOfRevenue | 999.12K | 4.18M | 5.48M | 11.57M |
| TotalRevenue | 3.92M | 6.81M | 34.22M | 97.89M |
| OperatingRevenue | 3.92M | 6.81M | 34.22M | 97.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 161.62K | 161.62K | 129.39K | |
| OrdinarySharesNumber | 1.10M | 1.04M | 1.03M | 1.13M |
| ShareIssued | 1.26M | 1.20M | 1.16M | 1.13M |
| TotalDebt | 2.15M | 2.99M | 347.92K | 0.00 |
| TangibleBookValue | 28.21M | 59.61M | 87.75M | 92.57M |
| InvestedCapital | 54.31M | 86.01M | 114.52M | 134.48M |
| WorkingCapital | 24.98M | 56.39M | 88.86M | 102.52M |
| NetTangibleAssets | 28.21M | 59.61M | 87.75M | 92.57M |
| CapitalLeaseObligations | 2.15M | 2.99M | 347.92K | 0.00 |
| CommonStockEquity | 54.31M | 86.01M | 114.52M | 134.48M |
| TotalCapitalization | 54.31M | 86.01M | 114.52M | 134.48M |
| TotalEquityGrossMinorityInterest | 54.31M | 86.01M | 114.52M | 134.48M |
| StockholdersEquity | 54.31M | 86.01M | 114.52M | 134.48M |
| GainsLossesNotAffectingRetainedEarnings | 418.44K | 146.70K | 293.14K | 0.00 |
| OtherEquityAdjustments | 418.44K | 146.70K | 293.14K | |
| TreasuryStock | 15.58M | 15.58M | 14.21M | 0.00 |
| RetainedEarnings | -33.04M | 4.60M | 39.93M | 54.17M |
| AdditionalPaidInCapital | 102.47M | 96.81M | 88.47M | 80.27M |
| CapitalStock | 37.90K | 36.11K | 34.75K | 33.82K |
| CommonStock | 37.90K | 36.11K | 34.75K | 33.82K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 9.69M | 9.31M | 8.57M | 25.56M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.37M | 3.56M | 4.69M | 12.96M |
| OtherNonCurrentLiabilities | 422.08K | 748.11K | 1.04M | 4.67M |
| NonCurrentAccruedExpenses | 0.00 | |||
| TradeandOtherPayablesNonCurrent | 713.64K | 659.19K | 1.18M | 1.07M |
| NonCurrentDeferredLiabilities | 0.00 | 2.42M | 7.23M | |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 2.42M | 7.23M | |
| LongTermDebtAndCapitalLeaseObligation | 1.24M | 2.15M | 50.71K | 0.00 |
| LongTermCapitalLeaseObligation | 1.24M | 2.15M | 50.71K | 0.00 |
| CurrentLiabilities | 7.32M | 5.75M | 3.87M | 12.60M |
| OtherCurrentLiabilities | 502.82K | 891.67K | 1.69M | 5.77M |
| CurrentDeferredLiabilities | 40.86K | 362.45K | 0.00 | 150.00K |
| CurrentDeferredRevenue | 40.86K | 362.45K | 0.00 | 150.00K |
| CurrentDebtAndCapitalLeaseObligation | 915.62K | 838.39K | 297.21K | |
| CurrentCapitalLeaseObligation | 915.62K | 838.39K | 297.21K | 0.00 |
| PayablesAndAccruedExpenses | 5.86M | 3.66M | 1.89M | 6.68M |
| CurrentAccruedExpenses | 2.56M | 2.17M | 934.45K | 3.86M |
| Payables | 3.29M | 1.48M | 952.30K | 2.82M |
| TotalTaxPayable | 0.00 | 2.21M | ||
| IncomeTaxPayable | 0.00 | 2.21M | ||
| AccountsPayable | 3.29M | 1.48M | 952.30K | 607.51K |
| TotalAssets | 64.00M | 95.32M | 123.09M | 160.03M |
| TotalNonCurrentAssets | 31.71M | 33.18M | 30.35M | 44.91M |
| NonCurrentDeferredAssets | 0.00 | |||
| NonCurrentDeferredTaxesAssets | 0.00 | |||
| NonCurrentNoteReceivables | 0.00 | 75.00K | ||
| InvestmentsAndAdvances | 731.07K | 773.38K | 672.68K | 1.00M |
| LongTermEquityInvestment | 731.07K | 773.38K | 672.68K | 1.00M |
| InvestmentsinJointVenturesatCost | 731.07K | 773.38K | 672.68K | 1.00M |
| GoodwillAndOtherIntangibleAssets | 26.10M | 26.40M | 26.77M | 41.90M |
| OtherIntangibleAssets | 26.10M | 26.40M | 26.77M | 27.20M |
| Goodwill | 0.00 | 14.71M | ||
| NetPPE | 4.88M | 6.00M | 2.91M | 1.93M |
| AccumulatedDepreciation | -3.28M | -2.23M | -1.37M | -622.15K |
| GrossPPE | 8.16M | 8.23M | 4.28M | 2.56M |
| Leases | 947.67K | 548.65K | 224.96K | 3.16K |
| OtherProperties | 7.04M | 7.51M | 3.95M | 2.48M |
| MachineryFurnitureEquipment | 173.67K | 173.67K | 112.04K | 75.40K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 32.29M | 62.14M | 92.73M | 115.12M |
| OtherCurrentAssets | 1.34M | 1.60M | 761.19K | 2.34M |
| PrepaidAssets | 2.34M | |||
| Inventory | 1.07M | 1.66M | 5.31M | 2.00M |
| FinishedGoods | 567.28K | 700.47K | 1.33M | 983.09K |
| RawMaterials | 505.44K | 964.26K | 3.98M | 1.02M |
| Receivables | 132.57K | 330.88K | 5.40M | 20.91M |
| TaxesReceivable | 0.00 | 26.95K | 1.87M | 0.00 |
| NotesReceivable | 0.00 | 75.00K | 75.00K | |
| AccountsReceivable | 132.57K | 303.93K | 3.45M | 20.84M |
| AllowanceForDoubtfulAccountsReceivable | -110.06K | -200.34K | -3.10M | -669.60K |
| GrossAccountsReceivable | 242.62K | 504.26K | 6.55M | 21.51M |
| CashCashEquivalentsAndShortTermInvestments | 29.75M | 58.55M | 81.26M | 89.86M |
| OtherShortTermInvestments | 26.81M | 43.63M | 58.29M | 1.26M |
| CashAndCashEquivalents | 2.94M | 14.92M | 22.97M | 88.61M |
| CashEquivalents | 0.00 | 10.60M | 10.14M | |
| CashFinancial | 2.94M | 4.32M | 12.83M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -29.90M | -23.45M | 5.14M | 40.41M |
| RepurchaseOfCapitalStock | 0.00 | -1.36M | -14.21M | 0.00 |
| IssuanceOfCapitalStock | 103.91K | 0.00 | 0.00 | |
| CapitalExpenditure | -748.35K | -1.37M | -1.43M | -669.46K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | |
| IncomeTaxPaidSupplementalData | 0.00 | 55.98K | 4.50M | 5.40M |
| EndCashPosition | 2.94M | 14.92M | 22.97M | 88.61M |
| BeginningCashPosition | 14.92M | 22.97M | 88.61M | 42.98M |
| ChangesInCash | -11.98M | -8.06M | -65.63M | 45.63M |
| FinancingCashFlow | 103.91K | -1.36M | -14.03M | 450.40K |
| CashFlowFromContinuingFinancingActivities | 103.91K | -1.36M | -14.03M | 450.40K |
| ProceedsFromStockOptionExercised | 0.00 | 177.87K | 450.40K | |
| NetCommonStockIssuance | 103.91K | -1.36M | -14.21M | 0.00 |
| CommonStockPayments | 0.00 | -1.36M | -14.21M | 0.00 |
| CommonStockIssuance | 103.91K | 0.00 | 0.00 | |
| InvestingCashFlow | 17.07M | 15.39M | -58.17M | 4.10M |
| CashFlowFromContinuingInvestingActivities | 17.07M | 15.39M | -58.17M | 4.10M |
| NetInvestmentPurchaseAndSale | 17.96M | 16.75M | -56.74M | 3.08M |
| SaleOfInvestment | 58.77M | 127.25M | 11.26M | 3.08M |
| PurchaseOfInvestment | -40.80M | -110.50M | -68.00M | 0.00 |
| NetBusinessPurchaseAndSale | -143.75K | 0.00 | 0.00 | 1.69M |
| SaleOfBusiness | 0.00 | 1.69M | ||
| PurchaseOfBusiness | -143.75K | 0.00 | ||
| NetPPEPurchaseAndSale | -748.35K | -1.37M | -1.43M | -669.46K |
| PurchaseOfPPE | -748.35K | -1.37M | -1.43M | -669.46K |
| OperatingCashFlow | -29.16M | -22.08M | 6.57M | 41.08M |
| CashFlowFromContinuingOperatingActivities | -29.16M | -22.08M | 6.57M | 41.08M |
| ChangeInWorkingCapital | 2.75M | 5.64M | 6.19M | -2.90M |
| ChangeInOtherWorkingCapital | -321.59K | 362.45K | -150.00K | -155.31K |
| ChangeInPayablesAndAccruedExpense | 2.21M | 1.25M | -4.69M | 2.34M |
| ChangeInPayable | 2.21M | 1.25M | -4.69M | 2.34M |
| ChangeInAccountPayable | 2.16M | 1.77M | -2.48M | -299.94K |
| ChangeInTaxPayable | 54.46K | -522.10K | -2.20M | 2.64M |
| ChangeInIncomeTaxPayable | 54.46K | -522.10K | -2.20M | 2.64M |
| ChangeInPrepaidAssets | 412.06K | 1.08M | -224.09K | -2.05M |
| ChangeInInventory | 265.49K | 413.14K | -3.67M | 5.71M |
| ChangeInReceivables | 186.39K | 2.54M | 14.92M | -8.74M |
| ChangesInAccountReceivables | 186.39K | 2.54M | 14.92M | -8.74M |
| OtherNonCashItems | -701.37K | -3.46M | -12.68M | 930.08K |
| StockBasedCompensation | 5.43M | 8.34M | 7.54M | 5.51M |
| ProvisionandWriteOffofAssets | -15.04K | 612.81K | 2.46M | |
| AssetImpairmentCharge | 326.51K | 3.23M | 15.54M | 69.67K |
| DeferredTax | 0.00 | -2.42M | -4.81M | 930.08K |
| DeferredIncomeTax | 0.00 | -2.42M | -4.81M | 930.08K |
| DepreciationAmortizationDepletion | 1.38M | 1.23M | 1.28M | 335.36K |
| DepreciationAndAmortization | 1.38M | 1.23M | 1.28M | 335.36K |
| OperatingGainsLosses | -692.97K | -2.34M | 471.09K | 474.79K |
| EarningsLossesFromEquityInvestments | 186.07K | -100.70K | 332.97K | 430.43K |
| GainLossOnInvestmentSecurities | -870.75K | -2.24M | ||
| NetIncomeFromContinuingOperations | -37.64M | -35.33M | -14.24M | 36.66M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CODX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|